Clinical Trials Logo

Clinical Trial Summary

Gastric cancer remains one of the leading causes of cancer-related deaths worldwide. There is difference between different countries in the world in the incidence and outcome. Also Italy on its inside shows a variability between regions and Lombardy hold the most incidence and mortality Italian rate, with the province of Cremona as one of the leading area with its gastric cancer mortality rate. (http://www.aslcremona.it/html/atlante/introduzione.htm). Tumor specialized registry can be viewed as one of the main strategies for studying and monitoring the impact of an important cancer diagnosis. In addition the information obtained from it can be translated into preventive measures and health surveillance that might lead to a better control of this tumor in a province with a so high mortality rate. Project purpose is to define the incidence of gastric cancer in the province of Cremona and the correlation with environmental, familiar, genetic and social factors; to adopt prevention strategies to reduce the impact of the disease and to create a gastric cancer bio-bank, including blood and tissue samples, for collaborative research projects regarding molecular and cellular aspects of gastric cancer.


Clinical Trial Description

Background: Gastric cancer (GC) is the 5th most common cancer and the 3rd leading cause of cancer-related deaths worldwide. GC incidence and mortality rates vary widely across different geographical areas. In Italy the province of Cremona is characterized by an high incidence, compared with the national one. For these reason a specialized population based registry was set up.

Methods: Up to now the collection encompasses all the GC cases diagnosed in Cremona province from January 1st 2010 until December 31st 2015. The main data sources were represented by the pathological records and the patient clinical charts. Data were collected following AIRTum (Associazione Italiana Registri Tumori) and IARC (International Agency for Research on Cancer) cancer registration recommendations. Territory of Cremona province comprises 3 main public hospitals and 3 private structures. All of them refer to 2 pathology services. All these facilities were involved in the project. A minority of patients usually ask for different surgery and move to neighboring provinces, mainly Milan and Brescia. An official collaboration with these facilities was signed in order to have the access to the data of their patients who were inhabitants of the province of Cremona. A multidisciplinary team of clinicians (oncologists, gastroenterologists, general practitioners, surgeons), pathologists, geneticists and methodologists (epidemiologists, hygienists) was involved in the project.

The registration of an incident case usually began with the pathological confirmation of diagnosis of cancer. Subsequently, medical records were obtained. For each case the following variables were registered: personal and familiar data; imaging studies performed; details on surgery and other treatments received; host genetic background and biomolecular characteristic, social and environmental factors. All data were collected, recorded, protected and processed in accordance to AIRTum-IARC (International Agency for Research on Cancer) cancer registration recommendations and national privacy laws.

Any age at diagnosis was included. At the time of diagnosis patients had to be inhabitants of the province of Cremona (districts of Crema, Cremona or Casalmaggiore). Only diagnoses of primary gastric neoplasms were considered. Precancerous lesions and relapsed tumor diagnoses were not considered. For the specific purposes of our study, we didn't record cases diagnosed based on Death Certificate Only (DCO)"in situ" tumors were also included.

Site of the tumor at diagnosis was stomach or gastro-esophageal junction (GEJ), ref. cod. ICD-X C16, according to the UICC, 7th ed.

All gastric malignancies were considered: gastric cancer; lymphoma; sarcoma and GIST. Gastric cancer was classified according to the Lauren's classification system, which distinguishes two main histological types: "intestinal" and "diffuse" . "Mixed" gastric carcinomas composed of intestinal and diffuse components have also been identified.

The primary tumor location was divided into three groups in consideration not only of the oncological but also of the surgical approach. Such groups were 1) GEJ-cardia; 2) body-fundus; 3) antrum-pylorus-angulus.

The TNM classification was recorded and the corresponding pathological stage was determined according to the 7th edition of the Union for International Cancer Control (UICC) and hereditary cases according to International GC Linkage Consortium guidelines.

Evaluation of the infection of Helicobacter pylori (HP) was performed by immunohistochemistry (IHC) in health gastric mucosa using the GIEMSA stain method. The HER-2 oncogene overexpression was evaluated in tumour gastric mucosa by the IHC method Dako Hercept TestTM. Results were confirmed by Fluorescent in Situ Hybridization (FISH) when IHC positivity score was 2.

To individuate Hereditary Diffuse Gastric Cancer (HDGC) cases, criteria by International GC Linkage Consortium 2010 guidelines were followed.

Incidence, standard errors, and 95% confidence intervals (CI) were calculated according to the International Agency for Research on Cancer (IARC) general guidelines. As for CIs, the method that considered the approximation to the Poisson distribution was chosen. Age-specific incidence rates were stratified into 18 subgroups by 5-year age interval (0 - 4, to 85+ years). Raw age-specific (5-years classes) and age-standardised (age-adjusted) rates were calculated per 100,000 inhabitants. For raw rates the denominator was the resident population census at 31st December of each year, available online at the official site of Cremona province. An age-standardized rate (ASR) is a weighted average of the age-specific (raw) rate, where the weight is the proportion of individuals in the corresponding age group of a standard population. Age-standardised rates were calculated using the standard age-structure of the European (EU) and World (W) standard population. This corrects the potential confounding effect derived from the differences in age between different populations. The trend of incidence, expressed as "Annual Percent Change" (APC) was evaluated using Join Point (National Cancer Institute, Bethesda, MD) in order to identify significant changes. Overall survival analysis was carried out by Kaplan-Meier methods and statistically significant differences were evaluated by Log-Rank Test . Survival hazard ratio was evaluated by Cox regression model, subsequently the testing of the proportion of hazard. Cumulative risks and other variables, including age at diagnosis, anatomical subsite, morphology of the tumour, TNM stage at diagnosis, presence of HP infection, HER-2 amplification status, 5-year survival and 1-year mortality rate were reported too. Descriptive statistics were used to summarize the data and parametric and non-parametric tests were used to evaluate differences between groups. Statistical analysis was carried out by STATA 13 software package (Texas, USA). A p-value less than 0.05 vas considered as statistically significant. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01662739
Study type Observational
Source Medicina e Arte Onlus
Contact Rodolfo Passalacqua, MD
Email r.passalacqua@asst-cremona.it
Status Recruiting
Phase N/A
Start date January 2010
Completion date December 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2